Tag: Ingelheim

Posted on

Propeller Health and Boehringer Ingelheim Collaborate on COPD, Asthma Tools for Better Health – COPD News Today


Drug Discovery & Development

Propeller Health and Boehringer Ingelheim Collaborate on COPD, Asthma Tools for Better Health
COPD News Today
Boehringer Ingelheim Pharmaceuticals and Propeller Health are partnering to use digital health tools and services to help patients with asthma and chronic obstructive pulmonary disease (COPD) to better cope with their condition. Under the terms of the …
FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim's STIOLTO RESPIMAT for COPD …PR Newswire (press release)
Boehringer Ingelheim Enters Commercial Partnership with Propeller HealthPharmaceutical Technology Magazine (press release) (blog)

all 3 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma … – Drug Discovery & Development

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
Drug Discovery & Development
Boehringer Ingelheim announced new data from large scale, Phase 3 studies showing that once-daily tiotropium delivered via the Respimat inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the …
Tiotropium as Asthma Add-On Treatment Shows PromiseMonthly Prescribing Reference

all 7 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma … – PR Newswire (press release)

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
PR Newswire (press release)
RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ — Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat® inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, …

and more »

View full post on asthma – Google News

Posted on

Phase III Success for Boehringer Ingelheim Asthma Drug – Genetic Engineering News

Phase III Success for Boehringer Ingelheim Asthma Drug
Genetic Engineering News
Boehringer-Ingelheim said today its once-daily asthma drug tiotropium, delivered via Respimat® Soft Mist™ Inhaler, produced favorable Phase III results by increasing the time to first severe exacerbation, and time to first episode of asthma worsening …
Boehringer Ingelheim's tiotropium shows promising results in patients with …News-Medical.net
Phase III results: tiotropium* Respimat® effective in symptomatic asthma …EON: Enhanced Online News (press release)
Boehringer Ingelheim reports positive data from symptomatic asthma trialsZenopa

all 5 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma … – The Pharma Letter

Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma …
The Pharma Letter
German family-owned drug major Boehringer Ingelheim presented a new subset of data from the Phase III UniTinA-asthma program relating to its already-marketed drug Spiriva (tiotropium) at the 2013 American Academy of Allergy, Asthma & Immunology …
Boehringer Ingelheim drug shows benefits in new asthma trialZenopa

all 2 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic … – PR Newswire (press release)

Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic …
PR Newswire (press release)
SAN ANTONIO, Feb. 23, 2013 /PRNewswire/ — Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma™ program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San …

and more »

View full post on asthma – Google News

Posted on

New data from Boehringer Ingelheim and Pfizer’s tiotropium clinical studies on … – News-Medical.net

New data from Boehringer Ingelheim and Pfizer's tiotropium clinical studies on …
News-Medical.net
New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic for …
BOEHRINGER INGELHEIM GMBH : Key results from new tiotropium studies in …4-traders

all 6 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with … – PR Newswire (press release)

Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with …
PR Newswire (press release)
Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma™ is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult …
Promising Phase II Data With Once-Daily Tiotropium may Lead to New Treatment …EIN News (press release)
Results of Phase II Study of Boehringer Ingelheim's Investigational …MarketWatch (press release)

all 4 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with … – MarketWatch (press release)

Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with …
MarketWatch (press release)
Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma(TM) is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult …
Boehringer Ingelheim Announces Positive Phase II Results for Once-Daily …EON: Enhanced Online News (press release)
Results of Phase II Study of Boehringer Ingelheim's Investigational …Sacramento Bee

all 23 news articles »

View full post on asthma – Google News